Valuation Roche Holding AG London S.E.

Stocks

Market Closed - London S.E. Other stock markets 16:20:00 17/07/2026 BST			5-day change	1st Jan Change
323.90 ^CHF	0.00%		0.00%	-1.29%

07-15	Berenberg Downgrades Qiagen Rating, Price Target Amid Rising Competition, Growth Concerns	MT
07-15	Roche's Gazyva/Gazyvaro Lands Priority Review From US FDA in Nephropathy	MT

Data adjusted to current consolidation scope

Fiscal Period: December	2021	2022	2023	2024	2025	2026	2027	2028
Market Cap ¹	306,810	239,812	197,073	205,191	262,098	266,472	-	-
Change	-	-21.84%	-17.82%	4.12%	27.73%	1.67%	-	-
Enterprise Value (EV) ¹	324,977	255,396	215,772	222,528	278,258	277,027	270,387	262,746
Change	-	-21.41%	-15.51%	3.13%	25.04%	-0.44%	-2.4%	-2.83%
P/E	23.4x	18.9x	17.1x	24.8x	20.5x	17.9x	16.6x	15.3x
PBR	13.2x	8.29x	5.91x	5.67x	7.8x	6.61x	5.57x	4.74x
PEG	-	-3.69x	-2.48x	-0.9x	0.4x	1.1x	2.23x	1.71x
Capitalization / Revenue	4.89x	3.79x	3.36x	3.39x	4.26x	4.26x	4.08x	3.89x
EV / Revenue	5.17x	4.04x	3.67x	3.68x	4.52x	4.43x	4.14x	3.84x
EV / EBITDA	13.2x	10.2x	9.82x	9.45x	11.3x	10.9x	9.98x	9.12x
EV / EBIT	14.8x	11.5x	11.2x	10.7x	12.7x	12.3x	11.2x	10.2x
EV / FCF	20.7x	19.6x	19.1x	14.5x	23.6x	17.9x	16.7x	15x
FCF Yield	4.83%	5.11%	5.23%	6.89%	4.24%	5.59%	5.99%	6.64%
Dividend per Share ²	9.3	9.5	9.6	9.7	9.8	10.01	10.25	10.53
Rate of return	2.45%	3.27%	3.93%	3.8%	2.99%	3%	3.07%	3.15%
EPS ²	16.2	15.37	14.31	10.31	16.04	18.72	20.11	21.91
Distribution rate	57.4%	61.8%	67.1%	94.1%	61.1%	53.5%	51%	48%
Net sales ¹	62,801	63,281	58,716	60,495	61,516	62,600	65,285	68,420
EBITDA ¹	24,692	25,015	21,976	23,538	24,608	25,403	27,106	28,820
EBIT ¹	21,897	22,173	19,240	20,823	21,833	22,592	24,172	25,728
Net income ¹	13,930	12,421	11,498	8,277	12,880	15,225	16,347	17,569
Net Debt ¹	18,167	15,584	18,699	17,337	16,160	10,555	3,915	-3,725
Reference price ²	379.10	290.50	244.50	255.50	328.20	334.20	334.20	334.20
Nbr of stocks (in thousands)	800,952	800,579	798,652	796,789	796,317	795,618	-	-
Announcement Date	03/02/22	02/02/23	01/02/24	30/01/25	29/01/26	-	-	-

¹CHF in Million²CHF

Estimates

Add to a list 0 selected To use this feature you must be a member Log in Sign up	P/E (N)	EV / Sales (N)	EV / EBITDA (N)	Dividend Yield (N)	Capi.($)
ELI LILLY AND COMPANY	35.04x	12.53x	26.21x	0.57%	1,051B
JOHNSON & JOHNSON	27.19x	6.2x	16.98x	2.12%	609B
ABBVIE INC.	33.15x	7.52x	15.43x	2.7%	450B
NOVARTIS AG	21.66x	5.55x	13.44x	2.84%	284B
ASTRAZENECA PLC	21.16x	4.46x	12.34x	1.97%	263B
NOVO NORDISK A/S	14.45x	5.41x	11.15x	3.44%	223B
AMGEN INC.	24.02x	6.35x	11.22x	2.75%	198B
GILEAD SCIENCES, INC.	-48.37x	5.78x	31.95x	2.42%	167B
PFIZER INC.	12.72x	3.11x	7.86x	6.89%	143B
Average	15.67x	6.32x	16.29x	2.86%	376.38B
Weighted average by Cap.	24.13x	7.96x	18.61x	2.11%